Nasal Polyps Treaments

  In recent study, The scientists concluded that eotaxin and RANTES could play a role in enhancing eosinophil recruitment into the lamina propria of nose polyps. Therefore, even though eosinophilia is less prominent in the Asian population with nose polyps, eosinophils might still be essential for the pathogenesis of nose polyps in Asian patients. Based on our and others’ results, a possible mechanism for tissue eosinophilia in nose polyps is that the proinflammatory cyto¬kines induce eotaxin and RANTES secretion from nose polyp fibroblasts, in turn selectively recruiting eosinophils from the circulation and resulting in eosinophilic infiltration and inflammation. Their findings suggest that in patients with vitamin D deficiency, the inability of low vitamin D level to counter the secretion of eotaxin and RANTES might lead to chronic inflammation and eosinophilia characteristic of nose polyps. Still, there are limitations in the present study. For example, the in vitro cell model m...

Nose polyposis remains one of the most challenging and recalcitrant diseases in clinical rhinology because of its complex etiology and predisposition to recurrence. However, it is well established that eotaxin and RANTES are central to tissue eosinophilia during nasal polyp formation .  Recent Study Based on the definition in European Position Paper on Rhinosinusitis and Nose Polyps (EPOS) 2007 , patients with recent diagnosis of Nose Polyps undergoing elective endoscopic sinus surgery at our hospital were recruited. Patients with malignancies or asthma were excluded from the study. All patients were asked to stop antiinflammatory medications, including antibiotics and topical steroids, for at least 2 weeks prior to admission. The tissues were isolated from the polyps of  Nose Polyps patients during the operations.  The scientists have previously shown that the serum level of 25-hydroxyvitamin D (25OHD), the major circulating form of vitamin D, in Nose Polyps patients w...

Yes, they can but chronic Rhinosinusitis with Nasal polyps is an often severe persistent airway disease, which in Europe and the US is mainly characterized by a type-2 inflammatory reaction. In spite of current treatment recommendations such as topical GCS twice daily, recurrences after oral GCS or surgeries are frequently observed. About one-third of the patients with nasal polyp are considered control failures with the current treatment options. This indicates a clear unmet need to search for other treatment possibilities, which need to be structured in adequate diagnosis and treatment care pathways. It is possible that better surgical techniques such as the “reboot technique”, aiming to remove all inflamed mucosa of the sinuses, but leaving nasal mucosa untouched, would change this situation.The nasal epithelium covers the sinuses after just 4-6 weeks and forms a smooth ciliated epithelial barrier with goblet cells.   No additional complications have been observed with this tech...

  Nasal polyps affects more than 10% of the population in western countries, 12% in the United States;6 11% in the Europe and 8-11% in Asia.Chronic rhinosinusitis with nasal polyps (CRSwNP), a phenotype of CRS, is a persistent inflammatory disease of the paranasal sinuses, and in 10%-70% accompanied by asthma. Nasal polyps  is affecting more than 4% of the population, with about a third of patients not controlled with the current standard of care approach, consisting of topical and systemic glucocorticosteroids (GCS), antibiotics and (often repeated) sinus surgery.   In the last 15 years, several randomized double-blind studies on monoclonal antibodies in Nasal Polyps were performed. These studies demonstrated for the first time that biologics targeting type 2 immune reactions might be successful in nasal polyps. The target proteins, interleukin (IL)-4, IL-5, IL-13, and IgE were previously identified as key mediators in studies using nasal polyp tissues to measu...

No significant mortality is associated with nasal polyposis. Morbidity is usually associated with altered quality of life, nasal obstruction, anosmia, chronic sinusitis, headaches, snoring, and postnasal drainage. In certain situations, nasal polyps can alter the craniofacial skeleton because unremoved polyps can extend intracranially and into the orbital vaults. Polyposis recurrence is common following treatment with medical or surgical therapy if multiple benign polyps are present (see Treatment, Surgical Care). Single large polyps (eg, antral-choanal polyps) are less likely to recur. Endoscopic sinus surgery appears to improve both olfaction and quality of life in chronic rhinosinusitis patients with nasal polyps. In a study of 58 pediatric patients (< 18 years) with antrochoanal polyps who were treated with functional endoscopic sinus surgery (FESS), Pagella et al reported a recurrence rate of 20.5%. The literature contains sparse data comparing treatments. Galluzzi et al perfor...

The pathogenesis of nasal polyposis is unknown. Polyp development has been linked to chronic inflammation, autonomic nervous system dysfunction, and genetic predisposition. Most theories consider polyps to be the ultimate manifestation of chronic inflammation; therefore, conditions leading to chronic inflammation in the nasal cavity can lead to nasal polyps. The following conditions are associated with multiple benign polyps:  -Bronchial asthma - In 20-50% of patients with polyps -CF - Polyps in 6-44% of patients with CF [1] -Allergic rhinitis -AFS - Polyps in 85% of patients with AFS -Chronic rhinosinusitis -Primary ciliary dyskinesia -Aspirin intolerance - In 8-26% of patients with polyps -Alcohol intolerance - In 50% of patients with nasal polyps -Churg-Strauss syndrome - Nasal polyps in 50% of patients with Churg-Strauss syndrome -Young syndrome (ie, chronic sinusitis, nasal polyposis, azoospermia) -Nonallergic rhinitis with eosinophilia syndrome (NARES) - Nasal polyps in 20% o...